Pharmacotherapy for chronic obstructive pulmonary disease
Journal of the Korean Medical Association
;
: 545-551, 2018.
Article
in Korean
| WPRIM
| ID: wpr-766537
ABSTRACT
The goals of management of stable chronic obstructive pulmonary disease (COPD) are to reduce both current symptoms and future risks with minimal side effects from treatment. Identification and reduction of exposure to risk factors are important in the treatment and prevention of COPD. Appropriate pharmacologic therapy can reduce symptoms and exacerbations, and improve health status and exercise tolerance. To date, none of the existing medications for COPD has been shown to modify disease progression or reduce mortality. The classes of medication are bronchodilators including beta2-agonist, anticholinergics and anti-inflammatory drug including inhaled corticosteroid and phosphodiesterase-4 inhibitor such as roflumilast. Each treatment regimen needs to be individualized as the relationship between severity of symptoms, airflow limitation and severity of exacerbation can differ between patients.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Bronchodilator Agents
/
Risk Factors
/
Mortality
/
Exercise Tolerance
/
Disease Progression
/
Cholinergic Antagonists
/
Pulmonary Disease, Chronic Obstructive
/
Drug Therapy
/
Cyclic Nucleotide Phosphodiesterases, Type 4
/
Phosphodiesterase 4 Inhibitors
Type of study:
Etiology study
/
Prognostic study
/
Risk factors
Limits:
Humans
Language:
Korean
Journal:
Journal of the Korean Medical Association
Year:
2018
Type:
Article
Similar
MEDLINE
...
LILACS
LIS